Enovix Distributes New Warrants to Shareholders and Convertible Noteholders

Enovix Corporation, the US-based developer and manufacturer of advanced lithium-ion batteries, has distributed a new series of shareholder warrants carrying an initial exercise price of $3 per common share, introducing a financing mechanism intended to help the company manage outstanding convertible debt obligations.

The Nasdaq-listed company announced on November 18, 2026, that eligible shareholders and holders of certain convertible senior notes would receive warrants under a distribution previously approved by its board of directors.

The warrants provide investors with the right, but not the obligation, to purchase additional Enovix common shares at a predetermined price.

The company has also introduced an alternative exercise mechanism allowing holders to surrender eligible convertible notes instead of making cash payments.

This structure is designed to create opportunities for Enovix to retire outstanding debt, preserve liquidity and potentially raise additional capital.

The announcement comes as the battery technology company continues investing in its proprietary silicon-anode technology while managing the financial requirements associated with manufacturing expansion and commercialisation.

Key Details of Enovix's November 2026 Warrant Distribution

Particulars

Details

Company

Enovix Corporation

Nasdaq stock symbol

ENVX

Warrant trading symbol

ENVXW

Announcement and distribution date

November 18, 2026

Shareholder record date

November 13, 2026

Warrant allocation

One warrant for every four shares

Initial cash exercise price

$3 per share

Shares purchasable per warrant

One common share

Alternative exercise method

Eligible 2028 convertible notes

Note exercise ratio

$1,000 principal for 333 warrants

Scheduled expiration

April 28, 2028

Initial early-expiration price threshold

$3.30

Warrants distributed

At no cost to eligible holders

Primary financial objective

Improve capital flexibility and address convertible debt

The warrants are expected to begin trading separately from Enovix common stock on Nasdaq under the symbol ENVXW on November 19, subject to applicable approvals.

How the Enovix Shareholder Warrant Distribution Works

Enovix established November 13, 2026, as the record date for determining which shareholders were eligible to receive warrants.

Shareholders generally needed to purchase or hold their shares no later than November 12 to qualify as holders of record.

Under the distribution formula, investors receive one warrant for every four common shares held.

Fractional warrants are rounded down to the nearest whole warrant.

For example, an investor holding 400 Enovix shares on the record date receives 100 warrants.

Each warrant provides the right to purchase one additional common share for $3 in cash, subject to the applicable terms and adjustments.

The warrants are distributed without requiring an initial payment.

However, investors who choose to exercise their warrants for cash must pay the applicable exercise price.

Receiving a warrant therefore does not mean that an investor automatically receives additional common shares.

The additional shares are issued only if the warrant is validly exercised under its terms.

Shareholders Can Exercise, Hold or Sell Their Warrants

Eligible investors have several options after receiving the warrants.

They may exercise the warrants by paying the required cash amount and acquiring additional Enovix shares.

They may also retain the warrants while evaluating future market conditions.

Because the warrants are transferable, holders may be able to sell them through the market once trading begins, subject to applicable trading arrangements.

Investors are not required to exercise their warrants.

A warrant's market value can change depending on the underlying share price, remaining time until expiration and other factors.

If the company's stock trades below the $3 exercise price, exercising a warrant for cash would generally be less attractive than purchasing shares directly at the lower market price.

However, the warrant itself may still have value because it provides the possibility of acquiring shares at the specified price before expiration.

Warrants can also expire without value if they are not exercised or sold before the applicable deadline.

Enovix Introduces Convertible Note Exercise Alternative

A distinctive feature of the distribution is the ability to exercise warrants by surrendering certain outstanding convertible senior notes.

Under the announced terms, holders may exercise 333 warrants by delivering $1,000 in principal amount of Enovix's 3.00% Convertible Senior Notes due 2028.

The transaction results in the issuance of 333 common shares.

Enovix would then retire and cancel the notes received through the exercise process.

This provides an alternative to the conventional cash exercise mechanism.

Instead of receiving cash from the warrant holder, the company reduces the principal amount of its outstanding debt.

The arrangement could also lower future interest obligations associated with the retired notes.

Importantly, Enovix's 4.75% Convertible Senior Notes due 2030 are not currently eligible to be surrendered under this exercise alternative unless the company permits otherwise.

The distinction matters because holders of both note series receive warrants, but the notes themselves do not have identical exercise privileges.

Why Enovix Wants to Reduce Its 2028 Convertible Debt

Convertible senior notes are debt instruments that may be converted into company shares under specified conditions.

They generally require the issuer to pay interest and meet repayment obligations unless the notes are converted, repurchased or otherwise retired.

Enovix's 2028 notes carry a 3.00% annual interest rate.

By accepting eligible notes in exchange for warrant exercises, Enovix can reduce outstanding debt without making an equivalent cash repayment of principal.

This may help preserve funds for manufacturing operations, product development and other corporate priorities.

The mechanism could also reduce future interest expenses.

For example, retiring $10 million in principal amount of 3.00% notes would eliminate approximately $300,000 in annual coupon obligations while those notes would otherwise have remained outstanding.

The actual financial benefit depends on the quantity of notes surrendered and the timing of retirement.

The company has not guaranteed that noteholders will exercise their warrants using this alternative.

Participation remains a decision for eligible investors.

Interim CEO Ryan Benton Highlights Debt Reduction Strategy

Enovix Interim Chief Executive Officer Ryan Benton described the warrant distribution as a way to give investors additional opportunities to participate in the company's development while addressing its outstanding debt.

Benton indicated that accepting the 2028 notes at face value could allow the company to retire debt and preserve cash.

He also explained that cash exercises could provide additional funding that Enovix might use to repurchase or retire outstanding notes.

The approach follows the company's earlier warrant dividend in 2025.

Management believes the previous distribution demonstrated shareholder interest in participating directly in the company's future growth.

The latest warrant programme builds on that structure while placing additional emphasis on financial flexibility.

However, the ultimate results will depend on investor participation, market conditions and the value of the warrants relative to the company's shares and debt securities.

Enovix Could Raise Approximately $165 Million From Cash Exercises

The company's securities registration documents indicate that full cash exercise of the relevant warrants could generate approximately $165.1 million in net proceeds after estimated commissions and offering expenses, excluding certain director and officer warrants.

The potential proceeds could be used for general corporate purposes, including repayment or retirement of debt.

However, the amount represents a hypothetical maximum under the stated assumptions.

It is not capital that Enovix has already received.

Actual proceeds may be significantly lower if warrant holders choose not to exercise, if warrants are exercised through note surrender or if market conditions make cash exercise unattractive.

The company therefore has two possible financial benefits from the programme.

Cash exercises could increase liquidity, while note-based exercises could reduce debt obligations.

Both outcomes involve issuing additional common shares.

Potential Shareholder Dilution Remains an Important Consideration

The warrant distribution creates the possibility of additional common shares entering circulation.

Enovix's registration documents cover the issuance of up to approximately 62.33 million common shares through warrant exercises.

As of November 13, 2026, the company reported approximately 212.48 million common shares outstanding.

If all registered warrant shares were issued, the number of outstanding shares could increase to approximately 274.81 million.

That would represent an increase of approximately 29.3% relative to the existing share count.

The actual dilution experienced by individual shareholders depends on whether they exercise their warrants, sell them or allow them to expire.

Shareholders who receive warrants have an opportunity to maintain some of their proportional ownership by purchasing additional shares.

However, doing so requires additional investment.

For investors who do not participate, the issuance of new shares could reduce their percentage ownership.

Dilution is therefore an important consideration alongside the potential benefits of debt reduction and capital raising.

Enovix Warrant Exercise Price Compared With Its Share Price

The $3 exercise price is an important feature of the warrant distribution.

According to the company's securities filing, Enovix common shares closed at $1.37 on November 17, 2026.

That price was below the warrant exercise price.

Consequently, immediate cash exercise would not have been economically attractive based solely on the prevailing share price at that time.

Investors would generally have been able to purchase common shares in the market for less than the $3 warrant exercise cost.

However, the warrants have a scheduled life extending into April 2028.

Their value therefore depends partly on expectations about future share-price movements.

If Enovix shares rise above the exercise price, the warrants could become economically attractive to exercise.

If the shares remain below the exercise price through expiration, the warrants may expire without being exercised.

The company's stock price can also change substantially before the expiration date.

Warrants Scheduled to Expire in April 2028

The warrants are scheduled to expire on April 28, 2028, at 5 p.m. New York City time.

However, the agreement includes an early-expiration mechanism.

The initial trigger requires Enovix's daily volume-weighted average share price to reach or exceed $3.30 on at least 20 trading days within any 30-consecutive-trading-day period following issuance.

The qualifying trading days do not need to occur consecutively.

If the condition is satisfied, the warrants may expire earlier under the terms of the agreement.

Enovix is required to announce the applicable expiration date.

This provision is important because investors may have less time to exercise or sell their warrants if the company's share price rises sufficiently.

Warrant holders must therefore monitor both the scheduled expiration date and any company announcements concerning early expiration.

Why the Early-Expiration Trigger Matters

Early-expiration provisions can encourage warrant holders to make exercise decisions once specified market conditions are met.

In Enovix's case, the initial trigger is linked to a share price of $3.30, representing 110% of the $3 exercise price.

If the company's stock trades above that threshold for the required number of days, the expiration mechanism may become effective.

This could accelerate potential cash inflows or debt retirement.

However, the provision also creates timing risks for investors.

A holder who expects the warrants to remain outstanding until April 2028 may need to act sooner if the price condition is satisfied.

The company has included provisions governing the exercise process, applicable adjustments and other operational requirements.

Investors should therefore consider the warrant agreement rather than relying exclusively on the scheduled expiration date.

Enovix Expands Financing Options While Developing Advanced Batteries

Enovix develops lithium-ion batteries using proprietary silicon-anode technology.

Its battery architecture is designed to provide higher energy density in compact devices while maintaining safety and performance.

The company is targeting applications including smartphones, smart eyewear, defence equipment, industrial devices and emerging edge artificial intelligence systems.

Battery manufacturers frequently require substantial investment before reaching large-scale commercial production.

Expenses can include research and development, manufacturing equipment, facility construction, testing and customer qualification.

These requirements can place pressure on cash resources, particularly during periods of production expansion.

Enovix's warrant distribution provides an additional financial mechanism that may support its ability to manage these obligations.

However, issuing warrants does not eliminate the underlying commercial and operational challenges associated with battery manufacturing.

The company's long-term performance will depend on product demand, manufacturing execution, customer relationships and its ability to generate sustainable revenue.

Silicon-Anode Battery Technology Remains Central to Enovix's Strategy

Conventional lithium-ion batteries commonly use graphite-based anodes.

Silicon offers the potential for higher energy storage capacity but presents engineering challenges because of expansion and contraction during charging cycles.

Enovix has developed a proprietary battery architecture intended to address some of these challenges.

The company is working to commercialise its technology across several product categories.

Consumer electronics represent one potential market because manufacturers increasingly seek batteries that deliver longer operating time without increasing device size.

Defence and industrial applications may also benefit from compact batteries with high energy density.

Edge AI devices, including smart eyewear and other portable electronics, create additional opportunities for advanced battery technology.

However, commercial success depends on achieving reliable manufacturing yields, competitive costs and customer acceptance.

Financial flexibility is therefore important as Enovix works to expand production and support product development.

Enovix's International Manufacturing Operations Support Growth Plans

Enovix is headquartered in Fremont, California, and maintains operations in India, South Korea and Malaysia.

Its international presence supports manufacturing, engineering and other business activities.

The company has been developing its manufacturing capabilities to serve customers across multiple industries.

Expanding battery production can require significant capital investment and specialised equipment.

Manufacturers must also meet demanding quality and safety standards.

These requirements can create substantial costs before production reaches commercially efficient volumes.

Enovix's debt-management strategy is therefore relevant to its broader manufacturing plans.

Reducing outstanding obligations or raising additional capital could provide greater flexibility in allocating resources.

Nevertheless, the financial benefits of the warrant programme remain dependent on whether investors exercise the securities.

What the Warrant Distribution Means for ENVX Shareholders

The distribution gives eligible shareholders a new security separate from their existing common shares.

Investors receive the warrants without making an initial payment.

However, the warrants introduce several financial considerations.

Their value depends on the market price of Enovix common shares and the time remaining until expiration.

They may also trade at prices influenced by market liquidity, volatility and investor expectations.

The $3 exercise price means that investors must consider the relationship between the warrant cost and the price of the underlying stock.

Potential dilution is another important factor.

If substantial numbers of warrants are exercised, the company will issue additional shares.

At the same time, the company may benefit from cash proceeds or reduced debt.

The overall effect on shareholder value will depend on whether the financial benefits outweigh the economic effects of dilution and other business risks.

What the Warrant Programme Means for Convertible Noteholders

Holders of Enovix's 2028 and 2030 convertible notes also receive warrants on a pass-through basis.

The allocation is designed to reflect the number of common shares into which their notes could be converted under the applicable terms.

However, the alternative note-surrender exercise mechanism currently applies to the 2028 notes.

Holders of eligible 2028 notes can use principal amounts to exercise warrants rather than paying cash.

This creates an additional option for investors evaluating their debt holdings.

They may compare the value of retaining their notes with the potential benefits of exchanging them through warrant exercise.

The decision depends on factors including the market value of the notes, the company's share price, interest payments and the remaining maturity period.

The arrangement does not automatically retire all outstanding 2028 notes.

Debt reduction will occur only to the extent that eligible noteholders participate in the specified exercise process.

Capital Structure Changes Could Influence Investor Expectations

The warrant programme may alter Enovix's capital structure over time.

Capital structure refers to the combination of debt, equity and other financing instruments used by a company.

If investors exercise warrants for cash, Enovix receives additional equity capital.

If eligible noteholders exercise warrants through note surrender, outstanding debt decreases while the number of common shares increases.

Both mechanisms can change the relationship between debt and equity.

A reduction in debt may improve certain financial metrics and reduce future interest obligations.

However, issuing additional shares can dilute existing shareholders.

Investors must therefore evaluate the potential benefits and costs together.

The ultimate financial impact cannot be determined solely from the warrant distribution announcement.

It will depend on the number of warrants exercised, the method of exercise and Enovix's subsequent financial performance.

What Happens Next for Enovix and Its Warrant Holders?

The warrants are expected to begin trading on Nasdaq under ENVXW on November 19, 2026, subject to the required approvals.

Eligible shareholders and convertible noteholders should receive their warrants through the applicable registration or brokerage arrangements.

Investors holding securities through intermediaries may need to contact their brokers regarding the timing of account crediting.

The company will monitor warrant exercises and the resulting effects on its cash resources and outstanding debt.

Investors will also watch the company's share price relative to the $3 exercise price and the $3.30 early-expiration threshold.

Enovix may provide additional updates regarding warrant exercises, debt retirement and changes to its capital structure through future regulatory filings.

The scheduled expiration remains April 28, 2028, unless an earlier expiration condition is triggered or the terms are otherwise amended.

Conclusion

Enovix's November 18, 2026, warrant distribution introduces a financing mechanism designed to improve the battery technology company's financial flexibility while addressing outstanding convertible debt.

Eligible shareholders receive one warrant for every four common shares held on the November 13 record date, with each warrant providing the right to purchase one additional share for $3.

The programme also allows eligible holders to surrender $1,000 in principal amount of 2028 convertible notes to exercise 333 warrants.

This arrangement could help Enovix reduce debt obligations and preserve cash for its manufacturing and technology development priorities.

Cash exercises may also provide additional funding, although the amount ultimately raised remains uncertain.

The potential benefits must be considered alongside shareholder dilution, warrant expiration conditions and the company's ongoing operational requirements.

For investors, the central considerations are the relationship between the $3 exercise price and Enovix's market value, the potential reduction in outstanding debt and the company's ability to execute its battery commercialisation strategy.